Professional Records
Medicine Doctors
Shengli Cai Phones & Addresses
-
661 Skyline Dr, Lk Hopatcong, NJ 07849 (512) 581-2762
-
Lake Hopatcong, NJ
-
1150 Orange Leaf Dr, Christiansburg, VA 24073 (540) 382-8549
-
13200 Copper Croft Run, Blacksburg, VA 24060 (540) 553-0572
-
13200 Copper Croft Run APT L, Blacksburg, VA 24060
-
San Francisco, CA
-
1104 9Th St, Smithville, TX 78957 (512) 237-2449
-
Morgan, NJ
Resumes
Resumes
Senior Global Clinical Development Leader-Global Clinical Development, Oncology
View pageLocation:
Lake Hopatcong, NJ
Industry:
Pharmaceuticals
Work:
Bayer
Senior Global Clinical Development Leader-Global Clinical Development, Oncology
Daiichi Sankyo, Inc. 2011 - 2015
Tmcp Clinical Leader and Project Head, Oncology Translational Medicine
Novartis Oncology 2009 - 2011
Associate Dir, Otm
Md Anderson Cancer Center 2000 - 2006
Faculty Instructor
Peking University 1997 - 2000
Surgical Dept, People's Hospital
Senior Global Clinical Development Leader-Global Clinical Development, Oncology
Daiichi Sankyo, Inc. 2011 - 2015
Tmcp Clinical Leader and Project Head, Oncology Translational Medicine
Novartis Oncology 2009 - 2011
Associate Dir, Otm
Md Anderson Cancer Center 2000 - 2006
Faculty Instructor
Peking University 1997 - 2000
Surgical Dept, People's Hospital
Education:
Peking University Health Science Center 1997 - 2000
Clinical Study Leader
View pageLocation:
Lake Hopatcong, NJ
Industry:
Pharmaceuticals
Work:
Ds Group (Dharampal Satyapal Limited)
Clinical Study Leader
Clinical Study Leader
Publications
Us Patents
Dosage Regimen Of Mdm2 Inhibitor For Treating Cancers
View pageUS Patent:
20180296547, Oct 18, 2018
Filed:
Oct 21, 2016
Appl. No.:
15/769054
Inventors:
- Tokyo, JP
Shengli CAI - Lake Hopatcong NJ, US
Shengli CAI - Lake Hopatcong NJ, US
Assignee:
DAIICHI SANKYO COMPANY, LIMITED - Tokyo
International Classification:
A61K 31/4439
A61P 35/00
A61K 9/00
A61P 35/00
A61K 9/00
Abstract:
The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor.